|
|
Article: Antares Pharma Announces Notice of Allowance for Elestrin(TM) Patent by U.S. Patent & Trademark Office.
- Article from:
- Business Wire
- Article date:
- February 7, 2007
CopyrightCOPYRIGHT 2007 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
EWING, N.J. -- Antares Pharma, Inc. (Amex: AIS) announced receipt of notice of allowance from the United States Patent & Trademark Office (USPTO) covering the formulation used in Elestrin[TM] (estradiol gel) which was co-invented by Antares and our licensee, BioSante. The USPTO has stated that it intends to grant patent protection which covers the proprietary formulation used in Elestrin. The patent is expected to expire in 2021.
Two doses of Elestrin, 0.87 grams per day and 1.7 grams per day, were approved by the FDA. Elestrin 0.87 grams per day is the lowest dose of estradiol approved by the U.S. Food and Drug Administration (FDA) for the treatment of ...